Join us this March for the first ever CURE Patient-Focused Sessions, taking place at the Miami Breast Cancer Conference! 

×
To start your customized experience click the start button
Customize ?  
Start
Cancer Types
Quick Links
Award Programs
About Us
Careers
Contact Us
Newsroom
Privacy Policy
Terms & Conditions
 
Twitter
Face Book
YouTube
Instagram
 
 
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2018
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

Myeloma

Feature Video
Dr Noopur Raje opens this program with a brief discussion on the basics of multiple myeloma. She describes what the disease is, highlights key risk factors, and explains how she helps educate her patients on their diagnosis. Cynthia Harrington discusses her role as a nurse practitioner when working with multiple myeloma patients and why a team-based approach between healthcare providers and the patient is important.
Brielle Benyon
Patients with myeloma who took higher doses of Kyprolis plus dexamethasone tended to have better survival outcomes, according to a recent study.
Kristie L. Kahl
The combination of Darzalex (daratumumab), Revlimid (lenalidomide) and dexamethasone significantly reduced the risk for disease progression in patients with newly diagnosed multiple myeloma.
Peter Voorhees, M.D.
New findings could spark change in the way that some patients with multiple myeloma are treated.
Brielle Benyon
Take a look at content from CURE Magazine from 10 years ago to see how the myeloma space – and our magazine in general – has changed!
Brielle Benyon
In the general population, African Americans tend to have poorer myeloma outcomes; however, that may not be the case for veterans.
Bill Wimbiscus
Hear patient-to-patient advice on navigating the complicated landscape of cancer care (and its costs).
The Multiple Myeloma Research Foundation
"In the midst of all of the difficulty of trying to deal with something this terrible, having that hope in your back pocket is invaluable to my life and to my family." - Brian Smith, on living with multiple myeloma and participating in Moving Mountains for Multiple Myeloma's recent Iceland trek. 
Jason M. Broderick
The Food and Drug Administration (FDA) has approved Empliciti (elotuzumab) for use in combination with Pomalyst (pomalidomide) and low-dose dexamethasone, also known as EPd, for the treatment of patients with relapsed/refractory multiple myeloma following two or more prior therapies, including Revlimid (lenalidomide) and a proteasome inhibitor.
Ellen Miller-Sonet
Treating people with cancer requires the coordination of complex care, and adding a clinical trial to the mix can pose more challenges. 
Kristie L. Kahl
A recent study found that fatigue reported among newly diagnosed patients with multiple myeloma may predict survival outcomes.
×
×

Sign In

Not a member? Sign up now!
Continue without login
Continue
×

Sign Up

Patient Caregiver Advocate Other